How Clinicians Manage Their Patients Who May Need Antithrombotic Care

Sponsor
Lawson Health Research Institute (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05923658
Collaborator
(none)
2,500
2

Study Details

Study Description

Brief Summary

This study aims to assess the knowledge and provide an opportunity for education to clinician attendees of the Canadian Cardiovascular Congress (CCC) meeting using a series of simulated patient case scenarios.

Detailed Description

Health conditions requiring antithrombotic therapy are highly prevalent in Canada, contributing substantially to healthcare costs and patient quality of life. For example, over 60,000 Canadians will experience a heart attack per year.1 Alarming statistics such as this warrant appropriate treatment approaches from clinicians who specialize in cardiovascular conditions. The CCC is a national conference during which individuals with an interest or expertise in cardiovascular health from across the country attend. Leveraging this unique opportunity by implementing a simple educational endeavour during the 2023 event can provide instrumental insights on the most appropriate treatments recommended from the latest clinical practice guidelines to a wide set of practitioners; this could, in turn, potentially improve patient health outcomes.

This endeavour will take place at a set date from October 25th to 29th, 2023. Attendees of the CCC who approach a booth set up by the lead investigator of this project will be presented with the study letter of information and consent form on a tablet (i.e., an iPad). After providing an electronic informed consent to participate, a series of patient case scenarios that require antithrombotic care and therapy will be shown. For each case scenario, the attendee (now, considered a study participant) will be asked to indicate the treatment approach that he/she would choose. And finally, after reviewing all case scenarios and selecting the best treatment approach to his/her knowledge, the participant will be asked to provide an email address (which could be an anonymized one) to send the most appropriate treatment approaches for each case scenario. This last step allows the participant an educational opportunity to learn what the best practice approach is based on the most up-to-date clinical practice guidelines. The approximate total duration of the study is one-hour in total.

Study Design

Study Type:
Observational
Anticipated Enrollment :
2500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
How Clinicians Manage Their Patients Who May Need Antithrombotic Care
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Adherence to Clinical Practice Guideline Recommendations [1-Month.]

    Open-ended recommendations provided by all participants on how they would treat each patient case in each scenario will be qualitatively coded as follows: 1) adhering to the recommendations provided in the guidelines, 2) partly adhering the recommendations provided in the guidelines, and 3) not adhering to the recommendations provided in the guidelines. For each participant, a total score will be computed across all case scenarios to determine adherence level to the latest Canadian clinical practice guideline recommendations.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Any clinician (i.e., licensed medical doctor, nurse practitioner) attending the CCC's 2023 event from October 25th-29th, 2023 will be included in this endeavour so long as they have the ability to provide informed consent (i.e., can read, write, and understand the English language).
Exclusion Criteria:
  • None

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Lawson Health Research Institute

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Anthony Tang, Professor and Scientific Director, Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT05923658
Other Study ID Numbers:
  • Antithrombotic Care at the CCC
First Posted:
Jun 28, 2023
Last Update Posted:
Jun 28, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 28, 2023